The Wall Street Journal reports that Merck & Co. won a jury trial in its defense against a lawsuit that alleged the company’s drug Fosamax caused a woman osteonecrosis. The verdict’s announcement was made on Monday, February 14.
A state court jury in Atlantic City, New Jersey rejected claims from a woman from Pennsylvania that Fosamax, which is a drug used to treat osteoporosis, caused her osteonecrosis, a deterioration of the jaw, often referred to as ONJ. The woman also claimed the drug manufacturer failed to warn consumers properly about the risks of the drug and Fosamax side effects. The jury found that the drug did not cause the woman’s jaw and dental problems and that the company “acted properly.” The woman plans to appeal the case, stating the drug maker should not be allowed to keep getting away with hiding the risks of Fosamax.
Merck, which is based in Whitehouse Station, NJ, is currently facing approximately 1,180 cases of users who allege that Fosamax caused ONJ. This trial was the first Fosamax trial in state court. Three cases were previously tried in New York federal court, of which Merck won two and is appealing the loss of the third. In that case, the jury awarded the plaintiff $8 million but the judge reduced the amount to $1.5 million.
At Anapol Weiss, our Fosamax attorneys have handled many lawsuits regarding unsafe drugs, including popular pharmaceuticals and diet drugs. If you have suffered because you have taken Fosamax, contact our law office today to learn more about your legal rights when pursuing a lawsuit against a drug manufacturer. Call 866-735-2792 to schedule a free consultation today.